Canatu (CANATU) investor relations material

Strategic Direction, Vision, and Business Model

• Transitioning from technology validation to scalable value creation, leveraging a unique carbon nanotube (CNT) platform across semiconductor, automotive, and medical diagnostics sectors.

• Focused execution and disciplined capital allocation prioritize high-value, scalable applications, targeting a €3 billion addressable market by 2030, with semiconductors as the primary growth driver.

• Employs asset-light, scalable business models: reactor/licensing for high-integration, high-volume applications, and direct product sales for high-value, lower-volume segments, enabling flexibility and recurring revenues.

• Competitive edge built on proprietary Dry Deposition™ technology, robust patent portfolio (over 300 patents granted or pending), and deep customer integration, creating high switching costs.

• New business development follows a disciplined, partner-led, milestone-driven approach, leveraging public funding and ecosystem partnerships.

Market Opportunities and Technology Leadership

• Semiconductor: AI-driven demand for advanced chips and EUV lithography adoption fuel CNT pellicle scaling, with a target of 10–20 reactors installed and 50% market share by 2030; inflection point expected at 2.0nm and 1.4nm nodes between 2026–2029.

• Automotive: Electrification and autonomous driving trends drive demand for CNT-based ADAS camera heaters, full windshield heaters, and next-gen solar cells, with strategic partnerships (e.g., DENSO) supporting scale-up.

• Medical diagnostics: Focus on point-of-care hormone and sepsis testing, leveraging CNT sensors for rapid, sensitive, cost-effective diagnostics; commercialization targeted for 2030, with patient journey reduced from days to 20 minutes.

• New Business Development aims for 2–5 new product families in mass production post-2030, focusing on microsystems and electrochemical sensors.

• CNT technology offers high barriers to entry, with 20 years of development, over €100 million invested, and a strong competitive position.

Financial Targets and Growth Outlook

• 2030 targets: €100–150 million revenue and 25–30% EBIT margin, with semiconductors as the largest contributor and recurring revenues expected to exceed 50% of total.

• Growth in medical diagnostics and new business development expected to accelerate towards the end of the period, though from a smaller base.

• CapEx peaks in 2026 due to facility and inspection system investments (up to €14–18M), then stabilizes at €5–6 million annually; headcount growth of 10–35 FTEs per year anticipated to support scaling and innovation.

• Financial model built bottom-up, with revenue projections based on customer pipeline and market adoption scenarios; licensing model means a portion of total pellicle value is captured.

• Risk management through focused execution, milestone-driven validation, and leveraging manufacturing capabilities across business units.